Pharmacogenetics in Primary Care Psychotropics

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03232502

Enrollment

130

Registered

2017-07-28

Start date

2017-08-15

Completion date

2018-12-31

Last updated

2017-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression, Obsessive-Compulsive Disorder, Generalized Anxiety Disorder

Brief summary

Pragmatic trial of pharmacogenetic testing at the time of prescription for a selective serotonin reuptake inhibitor, tricyclic antidepressant or atypical antipsychotic. Does real time intervention improve patient outcomes?

Interventions

DIAGNOSTIC_TESTPharmacogenetic testing

Basic pharmacogenetic panel

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Over 18 * Prescribed a drug of interest for the first time

Exclusion criteria

* Previous pharmacogenetic testing available

Design outcomes

Primary

Measure	Time frame	Description
Patient oriented outcome1- Clinical Improvement	6 months	Clinically significant improvement as noted by physician (Subjective and PHQ-9)
Patient oriented outcome2- Adverse effects	6 months	Number of patients with specific, common side effects (from medical chart)
Patient oriented outcome3- Time to Improvement	Up to 6 months	Days to clinical improvement (from medical chart)
Patient oriented outcome5- Visits	6 months	Total number of visits to clinic with medication titration required (from medical chart)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026